Search alternatives:
treated decrease » greater decrease (Expand Search), greatest decrease (Expand Search), treatment decreased (Expand Search)
marked decrease » marked increase (Expand Search)
b treated » _ treated (Expand Search), i treated (Expand Search), 1 treated (Expand Search)
treated decrease » greater decrease (Expand Search), greatest decrease (Expand Search), treatment decreased (Expand Search)
marked decrease » marked increase (Expand Search)
b treated » _ treated (Expand Search), i treated (Expand Search), 1 treated (Expand Search)
-
1
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…(B) For each group, the median Ki-67 immunostained parathyroid sample closest to the group mean is shown. …”
-
2
-
3
Group-level narrow- and broad-band spectral changes after hemispherotomy reveal a marked EEG slowing of the isolated cortex, robust across patients.
Published 2025“…This decrease was larger in the disconnected than in the contralateral cortex. …”
-
4
-
5
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…<p>(A) Representative images showed calcium deposition (red). (B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
-
6
B2 decreases glycolytic intermediates in cells.
Published 2025“…The box indicates the clustering of decreased downstream glycolytic intermediates in B2-treated cells. …”
-
7
-
8
-
9
-
10
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…Summarized bar graphs showed EVO significantly decreased mRNA expression of pyroptotic markers (B) NLRP3 and (C) GSDM-D in CER treated P<sub>i</sub>-induced VSMCs. …”
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20